Secondary analysis of ANNEXA-I (459 patients with factor Xa inhibitor-associated intracerebral haemorrhage): shorter onset-to-treatment time, larger volume, higher diastolic BP and faster prescan growth predicted haematoma expansion; andexanet benefit held across these.
Secondary analysisn = 459
Shoamanesh et al. Predictors of Hematoma Expansion and Response to Andexanet in Patients With Intracerebral Hemorrhage: Secondary Analyses of the ANNEXA-I Randomized Clinical Trial